Ligand ID: CTC


Drugbank ID:
DB09093
(Chlortetracycline)


Indication:
Chlortetracycline is a tetracycline antibiotic, the first tetracycline to be identified. It was discovered in 1945 by Benjamin Minge Duggar working at Lederle Laboratories under the supervision of Yellapragada Subbarow. Duggar identified the antibiotic as the product of an actinomycete he cultured from a soil sample collected from Sanborn Field at the University of Missouri. The organism was named Streptomyces aureofaciens and the isolated drug, Aureomycin, because of their golden color.

Get human targets for CTC in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'CTC' AND SARS-COV-2 / COVID-19 STRUCTURES

1) User may click on the DrReposER ID (the first column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera throuh AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
PHE A 219
VAL A 297
THR A 257
PRO A 293
ILE A 281
1.77A15.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
GLN A  69
MET A  17
GLY A  71
GLY A 143
1.79A17.75
None
None
DMS  A 403 ( 4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
PHE A 219
GLU A 270
LEU A 205
GLY A 275
ILE A 281
1.68A15.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
GLY A 120
VAL A 157
GLY A 149
PRO A  99
GLY A  15
1.69A15.93
None
None
None
None
DMS  A 403 (-3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
GLY A 120
LEU A  27
THR A  25
GLY A  23
VAL A  36
1.54A15.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
GLY A 149
PHE A 112
GLY A 143
GLY A 174
ILE A 136
1.65A15.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
GLY A  15
GLU A  14
GLY A 149
GLY A 120
VAL A  36
1.59A15.93
DMS  A 403 (-3.8A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
PHE A   8
THR A 292
GLY A 109
GLY A 149
ILE A 152
1.61A15.93
DMS  A 402 (-3.8A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
GLY A  11
VAL A  68
GLY A  71
PHE A 159
VAL A 148
1.75A15.93
None
None
DMS  A 403 ( 4.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6lze VIRAL PROTEASE
(SARS-CoV-2)		5 / 12
GLY A 120
LEU A  27
THR A  25
GLY A  23
VAL A  36
1.53A21.36
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6m0j SPIKE RECEPTOR
BINDING DOMAIN
(SARS-CoV-2)		5 / 12
PHE E 377
VAL E 524
GLY E 526
GLY E 431
ILE E 434
1.21A22.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6m0k VIRAL PROTEASE
(SARS-CoV-2)		5 / 12
GLY A 120
LEU A  27
THR A  25
GLY A  23
VAL A  36
1.51A21.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6m17 RECEPTOR BINDING
DOMAIN
(SARS-CoV-2)		6 / 12
PHE E 400
LEU E 425
THR E 430
GLY E 431
VAL E 407
ILE E 402
1.53A21.27
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
GLU A 166
GLY C 302
GLY A 138
PHE A 112
VAL A 114
1.47A21.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
VAL B 297
THR B 304
GLY B 302
PRO B 252
VAL B 261
1.53A21.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
PHE C   8
THR C 292
GLY C 109
GLY C 149
ILE C 152
1.57A21.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
PHE D   8
THR D 292
GLY D 109
GLY D 149
ILE D 152
1.54A21.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
GLN B  69
MET B  17
GLY B  71
GLY B 143
1.79A23.29
None
None
None
3WL  B 401 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 12
GLU B 166
GLY D 302
GLY B 138
PHE B 112
VAL B 114
1.45A21.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6m2q 3CL PROTEASE
(SARS-CoV-2)		5 / 12
GLY A 195
THR A 169
GLY A 170
GLY A 183
VAL A 186
1.57A21.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6m2q 3CL PROTEASE
(SARS-CoV-2)		5 / 12
GLY A 120
LEU A  27
THR A  25
GLY A  23
VAL A  36
1.53A21.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6m71 NSP12
(SARS-CoV-2)		4 / 8
GLN A 815
MET A 756
PRO A 830
GLY A 596
1.73A17.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6m71 NSP12
(SARS-CoV-2)		5 / 12
HIS A 572
ARG A 640
LEU A 308
ILE A 632
SER A 635
1.69A12.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6m71 NSP12
(SARS-CoV-2)		5 / 12
GLY A 345
PRO A 296
GLY A 352
PHE A 652
VAL A 299
1.56A17.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6m71 NSP12
(SARS-CoV-2)		5 / 12
GLY A 179
GLU A 180
VAL A 190
LEU A 316
ILE A 244
1.51A17.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6m71 NSP12
NSP8
(SARS-CoV-2)		5 / 12
VAL A 405
LEU B 128
PRO B 183
VAL B 159
ILE B 156
1.53A17.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		6m71 NSP12
(SARS-CoV-2)		5 / 12
ARG A 555
GLN A 444
THR A 409
VAL A 410
GLN A 408
1.56A12.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6m71 NSP12
NSP7
(SARS-CoV-2)		5 / 12
PHE A 442
PRO A 412
VAL C  11
LEU C  55
ILE C  39
1.71A12.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
SER A1055
PRO A 807
THR A 874
GLN A1054
ILE A 818
1.67A10.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
SER A1055
PRO A 807
THR A 874
GLN A1054
ILE A 818
1.73A10.39
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
ARG C 905
PHE C 888
GLY C 880
PRO C1053
1.22A16.67
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE B 400
LEU B 425
THR B 430
GLY B 431
ILE B 402
1.15A15.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_A_CTCA1385_0
(TETX2 PROTEIN)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
GLN B 920
PHE B 898
ASN A 709
GLY B 799
MET B1050
1.47A16.67
None
None
NAG  A1304 (-1.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6vxs NSP3
(SARS-CoV-2)		5 / 12
GLY B  47
VAL B 155
LEU B  53
GLY B 130
PHE B 132
1.36A
None
SO4  B 204 (-3.7A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6vxs NSP3
(SARS-CoV-2)		5 / 12
GLY A  47
VAL A 155
LEU A  53
GLY A 130
PHE A 132
1.31A
None
SO4  A 203 (-4.0A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_A_CTCA1385_0
(TETX2 PROTEIN)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
GLN C 920
PHE C 898
ASN B 709
GLY C 799
MET C1050
1.50A16.38
None
None
NAG  B1311 (-1.9A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
HIS A 519
PHE A 565
ARG A 328
LEU A 552
ILE A 587
1.55A10.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE B 400
LEU B 425
GLY B 431
VAL B 407
ILE B 402
1.24A14.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
HIS C 519
PHE C 565
ARG C 328
THR C 547
ILE C 587
1.75A10.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
GLN B 920
PHE B 898
GLY B 798
MET B1050
1.31A16.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
HIS C 519
PHE C 565
ARG C 328
THR C 547
ILE C 587
1.75A10.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
GLN C 920
PHE C 898
GLY C 798
MET C1050
1.30A16.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_A_CTCA1385_0
(TETX2 PROTEIN)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
GLN B 920
PHE B 898
ASN A 709
GLY B 799
MET B1050
1.51A16.46
None
None
NAG  A1311 (-1.9A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
SER C 325
PHE C 541
ARG C 577
PRO C 579
THR C 531
1.74A10.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE A 377
VAL A 524
GLY A 526
GLY A 431
ILE A 434
1.24A14.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE A1121
ARG B1091
THR B1105
VAL B1104
GLN B1113
1.77A10.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		6 / 12
GLY A 141
PHE A 135
LEU A 190
GLY A 157
GLY A 126
VAL A 149
1.48A25.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
SER A 274
ASN A  75
PRO A 344
VAL A 276
ILE A 323
1.78A19.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w41 CR3022 FAB HEAVY
CHAIN
SPIKE PROTEIN S1
(Homo
sapiens;
SARS-CoV-2)		4 / 8
ARG H  58
GLY C 381
PRO C 426
GLY C 413
1.27A17.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		5 / 12
PHE C 377
VAL C 524
GLY C 526
GLY C 431
ILE C 434
1.17A17.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		5 / 12
PHE C 400
LEU C 425
GLY C 431
VAL C 407
ILE C 402
1.36A17.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		5 / 12
GLY C 404
GLY C 447
PHE C 400
VAL C 350
ILE C 418
1.42A17.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		5 / 12
GLN C 498
PHE C 497
GLY C 447
SER C 443
GLY C 504
1.64A15.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 8
GLN C 498
PHE C 497
GLY C 447
GLY C 504
1.76A15.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w41 CR3022 FAB HEAVY
CHAIN
SPIKE PROTEIN S1
(Homo
sapiens;
SARS-CoV-2)		5 / 12
GLY C 413
VAL C 382
GLY H  97
VAL C 512
ILE C 410
1.75A17.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w4h NSP16
(SARS-CoV-2)		5 / 12
GLU A7062
PRO A7013
GLY A7011
PHE A6985
ILE A6955
1.30A21.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6w4h NSP10
NSP16
(SARS-CoV-2)		5 / 12
HIS B4333
GLY A6875
SER A6872
GLY B4323
MET A6839
1.41A15.45
None
None
SAM  A7102 ( 4.5A)
None
BDF  B4403 (-4.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6w61 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
HIS B4333
GLY A6875
SER A6872
GLY B4323
MET A6839
1.37A
None
None
SAM  A7104 (-4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w61 NSP10
(SARS-CoV-2)		4 / 8
ARG B4331
PHE B4321
GLY B4322
GLY B4362
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
LEU A6893
THR A6880
GLY A6879
VAL A6916
ILE A7088
1.45A
None
None
SAM  A7104 (-3.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
LEU A6887
THR A6891
GLY A6890
PHE A6954
ILE A6925
1.71A18.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6w61 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
HIS B4333
GLY A6875
SER A6872
GLY B4322
MET A6839
1.53A
None
None
SAM  A7104 (-4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w61 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 8
ARG B4331
GLY A6871
GLY B4323
MET A6839
1.77A
None
SAM  A7104 (-4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w61 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 8
ARG B4331
GLY A6871
GLY B4322
MET A6839
1.58A
None
SAM  A7104 (-4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
GLN A 110
PHE A 294
PRO A 293
GLY A 251
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
GLY A 120
LEU A  27
THR A  25
GLY A  23
VAL A  36
1.52A
None
X77  A 401 ( 3.9A)
X77  A 401 (-4.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w6y NSP3
(SARS-CoV-2)		5 / 12
GLY B  46
VAL B 155
LEU B  53
GLY B 130
PHE B 132
1.49A
None
None
None
MES  B 201 ( 3.4A)
MES  B 201 ( 3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w6y NSP3
(SARS-CoV-2)		4 / 8
PHE B 132
GLY B 130
PRO B  98
GLY B 103
1.64A
MES  B 201 ( 3.4A)
MES  B 201 ( 3.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w6y NSP3
(SARS-CoV-2)		5 / 12
GLY B  47
VAL B 155
LEU B  53
GLY B 130
PHE B 132
1.30A
None
None
None
MES  B 201 ( 3.4A)
MES  B 201 ( 3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w6y NSP3
(SARS-CoV-2)		5 / 12
GLY A  46
VAL A  35
GLY A  85
PHE A 132
VAL A  96
1.79A18.73
None
None
None
AMP  A 201 ( 4.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w75 NSP16
(SARS-CoV-2)		4 / 8
ARG C7077
GLY C6962
PRO C6860
GLY C7054
1.65A17.04
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w75 NSP10
(SARS-CoV-2)		4 / 8
ARG B4331
PHE B4321
GLY B4322
GLY B4362
1.77A15.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w75 NSP10
(SARS-CoV-2)		4 / 8
ARG D4331
PHE D4321
GLY D4322
GLY D4362
1.75A15.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w75 NSP16
(SARS-CoV-2)		5 / 12
GLU A7062
PRO A7013
GLY A7011
PHE A6985
ILE A6955
1.24A17.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w75 NSP16
(SARS-CoV-2)		5 / 12
LEU A6887
THR A6891
GLY A6890
PHE A6954
ILE A6925
1.67A17.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6w75 NSP10
NSP16
(SARS-CoV-2)		5 / 12
HIS D4333
GLY C6875
SER C6872
GLY D4322
MET C6839
1.42A15.45
None
None
SAM  C7105 ( 4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6w75 NSP10
NSP16
(SARS-CoV-2)		5 / 12
HIS B4333
GLY A6875
SER A6872
GLY B4323
MET A6839
1.33A15.45
None
None
SAM  A7102 ( 4.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6w75 NSP10
NSP16
(SARS-CoV-2)		5 / 12
HIS B4333
GLY A6875
SER A6872
GLY B4322
MET A6839
1.44A15.45
None
None
SAM  A7102 ( 4.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w75 NSP16
(SARS-CoV-2)		5 / 12
GLY C6963
THR C6891
GLY C6890
PHE C6954
ILE C6925
1.78A17.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w75 NSP10
NSP16
(SARS-CoV-2)		4 / 8
ARG D4331
GLY C6871
GLY D4323
MET C6839
1.74A15.45
None
SAM  C7105 ( 4.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w75 NSP16
(SARS-CoV-2)		5 / 12
GLU C7062
PRO C7013
GLY C7011
PHE C6985
ILE C6955
1.42A17.00
None
None
NA  C7103 ( 4.1A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6w75 NSP16
(SARS-CoV-2)		5 / 12
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.75A19.52
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6w75 NSP10
NSP16
(SARS-CoV-2)		5 / 12
HIS D4333
GLY C6875
SER C6872
GLY D4323
MET C6839
1.29A15.45
None
None
SAM  C7105 ( 4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w75 NSP10
NSP16
(SARS-CoV-2)		4 / 8
ARG B4331
GLY A6871
GLY B4323
MET A6839
1.76A15.45
None
SAM  A7102 ( 4.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6w75 NSP16
(SARS-CoV-2)		5 / 12
LEU C6887
THR C6891
GLY C6890
PHE C6954
ILE C6925
1.73A17.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w75 NSP10
NSP16
(SARS-CoV-2)		4 / 8
ARG D4331
GLY C6871
GLY D4322
MET C6839
1.61A15.45
None
SAM  C7105 ( 4.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6w75 NSP10
NSP16
(SARS-CoV-2)		4 / 8
ARG B4331
GLY A6871
GLY B4322
MET A6839
1.60A15.45
None
SAM  A7102 ( 4.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wcf NSP3
(SARS-CoV-2)		4 / 8
PHE A 132
GLY A 130
PRO A  98
GLY A 103
1.62A
MES  A 201 (-2.5A)
MES  A 201 (-3.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wcf NSP3
(SARS-CoV-2)		5 / 12
GLY A  46
VAL A 155
LEU A  53
GLY A 130
PHE A 132
1.53A
MES  A 202 (-4.7A)
None
None
MES  A 201 (-3.2A)
MES  A 201 (-2.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wcf NSP3
(SARS-CoV-2)		5 / 12
GLY A  47
VAL A 155
LEU A  53
GLY A 130
PHE A 132
1.26A
MES  A 202 (-3.4A)
None
None
MES  A 201 (-3.2A)
MES  A 201 (-2.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wey NSP3
(SARS-CoV-2)		5 / 12
GLY A 251
VAL A 359
LEU A 257
GLY A 334
PHE A 336
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY F 287
PHE F 286
PRO F 279
GLY F 284
ILE E 320
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
PHE D 286
LEU C 331
GLY D 335
PRO C 309
ILE D 304
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
PHE B 286
LEU A 331
GLY B 335
PRO A 309
ILE B 304
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
PHE E 286
LEU F 331
GLY E 335
PRO F 309
ILE E 304
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY B 335
THR A 325
GLY A 328
PHE A 315
ILE A 320
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
PHE F 286
LEU E 331
GLY F 335
GLY E 316
ILE F 304
1.38A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY E 321
LEU F 339
THR E 329
GLY E 328
GLY F 335
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY D 335
THR C 325
GLY C 328
PHE C 315
ILE C 320
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
PHE B 286
LEU A 331
GLY B 335
GLY A 316
ILE B 304
1.39A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
PHE A 286
LEU B 331
GLY A 335
GLY B 316
ILE A 304
1.39A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
PHE F 286
LEU E 331
GLY F 335
PRO E 309
ILE F 304
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY E 335
THR F 325
GLY F 328
PHE F 315
ILE F 320
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY F 335
THR E 325
GLY E 328
PHE E 315
ILE E 320
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
PHE E 286
LEU F 331
GLY E 335
GLY F 316
ILE E 304
1.37A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
PHE D 286
LEU C 331
GLY D 335
GLY C 316
ILE D 304
1.36A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
PHE C 286
LEU D 331
GLY C 335
PRO D 309
ILE C 304
1.41A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
GLY A 335
THR B 325
GLY B 328
PHE B 315
ILE B 320
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
PHE A 286
LEU B 331
GLY A 335
PRO B 309
ILE A 304
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
PHE C 286
LEU D 331
GLY C 335
GLY D 316
ILE C 304
1.37A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		6 / 12
GLY E 278
GLU E 280
GLY F 335
GLY E 275
VAL E 270
ILE E 292
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 8
ARG B4331
GLY A6871
GLY B4323
MET A6839
1.75A
None
SAH  A7102 (-4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 8
ARG D4331
GLY C6871
GLY D4322
MET C6839
1.56A
None
SAH  C7102 (-4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 8
ARG D4331
GLY C6871
GLY D4323
MET C6839
1.72A
None
SAH  C7102 (-4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
ARG C7077
GLY C6962
PRO C6860
GLY C7054
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wjt NSP10
(SARS-CoV-2)		4 / 8
ARG D4331
PHE D4321
GLY D4322
GLY D4362
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wjt NSP10
(SARS-CoV-2)		4 / 8
ARG B4331
PHE B4321
GLY B4322
GLY B4362
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
GLU C7062
PRO C7013
GLY C7011
PHE C6985
ILE C6955
1.28A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
HIS D4333
GLY C6875
SER C6872
GLY D4323
MET C6839
1.23A
None
None
SAH  C7102 (-4.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
GLY B4362
VAL A6876
LEU B4345
GLY B4322
PHE D4272
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
HIS D4333
GLY C6875
SER C6872
GLY D4322
MET C6839
1.38A
None
None
SAH  C7102 (-4.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 8
ARG B4331
GLY A6871
GLY B4322
MET A6839
1.57A
None
SAH  A7102 (-4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
HIS B4333
GLY A6875
SER A6872
GLY B4322
MET A6839
1.36A
None
None
SAH  A7102 ( 4.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
HIS B4333
GLY A6875
SER A6872
GLY B4323
MET A6839
1.26A
None
None
SAH  A7102 ( 4.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
GLU A7062
PRO A7013
GLY A7011
PHE A6985
ILE A6955
1.29A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
HIS B  59
SER B 105
THR C 141
ILE C 146
SER C  78
1.76A21.78
 ZN  C 201 (-3.3A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
HIS D  59
SER D 105
THR A 141
ILE A 146
SER A  78
1.74A
 ZN  A 201 (-4.1A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
HIS D  59
SER D 105
THR A 141
ILE A 146
SER A  78
1.78A21.78
 ZN  A 201 (-4.1A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
HIS B  59
SER B 105
THR C 141
ILE C 146
SER C  78
1.69A21.78
 ZN  C 201 (-3.3A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wkq NSP16
(SARS-CoV-2)		5 / 12
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wkq NSP10
NSP16
(SARS-CoV-2)		4 / 8
ARG B4331
GLY A6871
GLY B4323
MET A6839
1.76A
None
SFG  A7103 ( 4.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6wkq NSP10
NSP16
(SARS-CoV-2)		5 / 12
HIS B4333
GLY A6875
SER A6872
GLY B4322
MET A6839
1.38A
None
None
SFG  A7103 ( 4.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wkq NSP10
(SARS-CoV-2)		4 / 8
ARG B4331
PHE B4321
GLY B4322
GLY B4362
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wkq NSP10
NSP16
(SARS-CoV-2)		4 / 8
ARG B4331
GLY A6871
GLY B4322
MET A6839
1.60A
None
SFG  A7103 ( 4.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wkq NSP16
(SARS-CoV-2)		5 / 12
GLU C7062
PRO C7013
GLY C7011
PHE C6985
ILE C6955
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wkq NSP16
(SARS-CoV-2)		5 / 12
GLU A7062
PRO A7013
GLY A7011
PHE A6985
ILE A6955
1.27A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wkq NSP10
NSP16
(SARS-CoV-2)		4 / 8
ARG D4331
GLY C6871
GLY D4323
MET C6839
1.74A
None
SFG  C7103 ( 4.1A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6wkq NSP10
NSP16
(SARS-CoV-2)		5 / 12
HIS B4333
GLY A6875
SER A6872
GLY B4323
MET A6839
1.27A
None
None
SFG  A7103 ( 4.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wkq NSP10
NSP16
(SARS-CoV-2)		4 / 8
ARG D4331
GLY C6871
GLY D4322
MET C6839
1.59A
None
SFG  C7103 ( 4.1A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wkq NSP16
(SARS-CoV-2)		4 / 8
ARG C7077
GLY C6962
PRO C6860
GLY C7054
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6wkq NSP10
NSP16
(SARS-CoV-2)		5 / 12
HIS D4333
GLY C6875
SER C6872
GLY D4322
MET C6839
1.40A
None
None
SFG  C7103 ( 4.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wkq NSP10
(SARS-CoV-2)		4 / 8
ARG D4331
PHE D4321
GLY D4322
GLY D4362
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6wkq NSP10
NSP16
(SARS-CoV-2)		5 / 12
HIS D4333
GLY C6875
SER C6872
GLY D4323
MET C6839
1.26A
None
None
SFG  C7103 ( 4.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		6 / 12
GLY B 141
PHE B 135
LEU B 190
GLY B 157
GLY B 126
VAL B 149
1.54A
None
None
None
None
ACT  B 408 (-4.2A)
ACT  B 408 ( 4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		6 / 12
GLY A 141
PHE A 135
LEU A 190
GLY A 157
GLY A 126
VAL A 149
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
GLY B 165
VAL B  10
GLY B  14
VAL B  85
ILE B  86
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
GLY A 120
LEU A  27
THR A  25
GLY A  23
VAL A  36
1.56A
None
U5G  A 401 ( 4.0A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
GLN A 110
PHE A 294
PRO A 293
GLY A 251
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY B  46
VAL B 155
LEU B  53
GLY B 130
PHE B 132
1.49A
APR  B 201 (-3.7A)
None
None
APR  B 201 (-3.3A)
APR  B 201 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY C  46
VAL C 155
LEU C  53
GLY C 130
PHE C 132
1.50A
APR  C 201 (-3.9A)
None
None
APR  C 201 (-3.0A)
APR  C 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE C 132
GLY C 130
PRO C  98
GLY C 103
1.70A
APR  C 201 (-3.5A)
APR  C 201 (-3.0A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY C  47
VAL C 155
LEU C  53
GLY C 130
PHE C 132
1.51A
APR  C 201 (-4.1A)
None
None
APR  C 201 (-3.0A)
APR  C 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY B  47
VAL B 155
LEU B  53
GLY B 130
PHE B 132
1.50A
APR  B 201 (-4.0A)
None
None
APR  B 201 (-3.3A)
APR  B 201 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY D  47
VAL D 155
LEU D  53
GLY D 130
PHE D 132
1.49A
APR  D 201 (-4.2A)
None
None
APR  D 201 (-3.2A)
APR  D 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE D 132
GLY D 130
PRO D  98
GLY D 103
1.75A
APR  D 201 (-3.5A)
APR  D 201 (-3.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY D  46
VAL D 155
LEU D  53
GLY D 130
PHE D 132
1.50A
APR  D 201 (-3.8A)
None
None
APR  D 201 (-3.2A)
APR  D 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE B 132
GLY B 130
PRO B  98
GLY B 103
1.77A
APR  B 201 (-3.6A)
APR  B 201 (-3.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY A  47
VAL A 155
LEU A  53
GLY A 130
PHE A 132
1.50A
APR  A 201 (-4.1A)
None
None
APR  A 201 (-3.5A)
APR  A 201 (-3.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY A  46
VAL A 155
LEU A  53
GLY A 130
PHE A 132
1.50A
APR  A 201 (-3.9A)
None
None
APR  A 201 (-3.5A)
APR  A 201 (-3.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PHE A 132
GLY A 130
PRO A  98
GLY A 103
1.73A
APR  A 201 (-3.1A)
APR  A 201 (-3.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
LEU A6893
THR A6880
GLY A6879
VAL A6916
ILE A7088
1.50A
None
None
SAH  A7101 (-3.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wq3 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 8
ARG B4331
GLY A6871
GLY B4322
MET A6839
1.61A
None
SAH  A7101 (-4.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6wq3 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
HIS B4333
GLY A6875
SER A6872
GLY B4323
MET A6839
1.28A
None
None
SO4  A7109 (-4.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wq3 NSP10
(SARS-CoV-2)		4 / 8
ARG B4331
PHE B4321
GLY B4322
GLY B4362
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_C_CTCC1385_0
(TETX2 PROTEIN)		6wq3 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		5 / 12
HIS B4333
GLY A6875
SER A6872
GLY B4322
MET A6839
1.48A
None
None
SO4  A7109 (-4.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6wq3 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 8
ARG B4331
GLY A6871
GLY B4323
MET A6839
1.73A
None
SAH  A7101 (-4.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wqd NSP7
NSP8
(SARS-CoV-2)		5 / 12
HIS A  36
ARG D  80
THR D  89
LEU C  20
SER C  15
1.52A20.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 12
GLY A 120
LEU A  27
THR A  25
GLY A  23
VAL A  36
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wrh PEPTIDASE C16
(SARS-CoV-2)		5 / 12
HIS A 272
SER A 111
PRO A 299
LEU A 253
ILE A 276
1.68A18.48
PO4  A 502 (-3.7A)
PO4  A 502 (-2.9A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
PHE A 219
VAL A 297
THR A 257
PRO A 293
ILE A 281
1.77A16.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY A 120
LEU A  27
THR A  25
GLY A  23
VAL A  36
1.53A16.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY A  11
VAL A  68
GLY A  71
PHE A 159
VAL A 148
1.75A16.59
None
None
DMS  A 406 ( 4.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY A  15
GLU A  14
GLY A 149
GLY A 120
VAL A  36
1.61A16.59
DMS  A 406 (-3.7A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
PHE A 219
GLU A 270
LEU A 205
GLY A 275
ILE A 281
1.72A16.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY A 149
PHE A 112
GLY A 143
GLY A 174
ILE A 136
1.65A16.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
PHE A   8
THR A 292
GLY A 109
GLY A 149
ILE A 152
1.58A16.59
DMS  A 403 (-3.8A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
GLY E 404
GLY E 447
PHE E 400
VAL E 350
ILE E 418
1.50A
DMS  E 902 (-3.4A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE A 377
VAL A 524
GLY A 526
GLY A 431
ILE A 434
1.17A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6yla HEAVY CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
ARG H  59
GLY E 381
PRO E 426
GLY E 413
1.08A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6yla HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
GLN L  95
ARG H  59
PRO H 105
GLY E 381
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE E 377
VAL E 524
GLY E 526
GLY E 431
ILE E 434
1.18A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE E 400
LEU E 425
GLY E 431
VAL E 407
ILE E 402
1.36A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6yla HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 12
PHE A 429
THR B 104
VAL A 382
LEU A 517
ILE C  34
1.60A17.89
None
None
DMS  A 905 (-4.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6yla HEAVY CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
ARG B  59
GLY A 381
PRO A 426
GLY A 413
1.14A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE A 400
LEU A 425
GLY A 431
VAL A 407
ILE A 402
1.39A
None
None
None
DMS  A 903 ( 4.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
GLY E 404
GLY E 447
PHE E 400
VAL E 350
ILE E 418
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6ym0 HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
GLN L  95
ARG H  59
PRO H 105
GLY E 381
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6ym0 HEAVY CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
ARG H  59
GLY E 381
PRO E 426
GLY E 413
1.12A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE E 377
VAL E 524
GLY E 526
GLY E 431
ILE E 434
1.14A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE E 400
LEU E 425
GLY E 431
VAL E 407
ILE E 402
1.34A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
GLY E 404
GLY E 447
PHE E 400
VAL E 350
ILE E 418
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
GLY A 404
GLY A 447
PHE A 400
VAL A 350
ILE A 418
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6yor IGG H CHAIN
IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
GLN C  95
ARG B  59
PRO B 105
GLY A 381
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE E 377
VAL E 524
GLY E 526
GLY E 431
ILE E 434
1.18A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6yor IGG H CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
ARG H  59
GLY E 381
PRO E 426
GLY E 413
1.09A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6yor IGG H CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
ARG B  59
GLY A 381
PRO A 426
GLY A 413
1.08A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6yor IGG H CHAIN
IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
GLN L  95
ARG H  59
PRO H 105
GLY E 381
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE A 377
VAL A 524
GLY A 526
GLY A 431
ILE A 434
1.18A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE A 400
LEU A 425
GLY A 431
VAL A 407
ILE A 402
1.35A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
PHE E 400
LEU E 425
GLY E 431
VAL E 407
ILE E 402
1.36A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
GLY A 120
LEU A  27
THR A  25
GLY A  23
VAL A  36
1.57A
None
PK8  A 401 ( 3.6A)
PK8  A 401 ( 4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
GLN A  69
MET A  17
GLY A  71
GLY A 143
1.77A
None
None
None
PK8  A 401 ( 4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PHE B 132
GLY B 130
PRO B  98
GLY B 103
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY E  47
VAL E 155
LEU E  53
GLY E 130
PHE E 132
1.36A
EPE  E 202 (-4.3A)
EDO  E 205 ( 4.2A)
None
EPE  E 202 ( 4.5A)
EPE  E 202 (-3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY D  47
VAL D 155
LEU D  53
GLY D 130
PHE D 132
1.41A
EDO  D 206 (-4.5A)
EDO  D 208 ( 4.2A)
None
EDO  D 205 ( 4.9A)
EDO  D 205 ( 3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY A  47
VAL A 155
LEU A  53
GLY A 130
PHE A 132
1.33A
None
None
None
EDO  A 202 ( 4.4A)
EDO  A 202 (-3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY A  46
VAL A 155
LEU A  53
GLY A 130
PHE A 132
1.50A
APR  A 201 (-4.2A)
APR  A 201 ( 4.8A)
None
APR  A 201 ( 3.2A)
APR  A 201 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY B  47
VAL B 155
LEU B  53
GLY B 130
PHE B 132
1.53A
APR  B 201 (-3.6A)
None
None
APR  B 201 (-3.2A)
APR  B 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PHE E 132
GLY E 130
PRO E  98
GLY E 103
1.68A
APR  E 201 (-3.5A)
APR  E 201 (-3.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PHE D 132
GLY D 130
PRO D  98
GLY D 103
1.72A
APR  D 201 (-3.3A)
APR  D 201 (-3.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY D  46
VAL D 155
LEU D  53
GLY D 130
PHE D 132
1.50A
APR  D 201 (-3.8A)
None
None
APR  D 201 (-3.2A)
APR  D 201 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PHE B 132
GLY B 130
PRO B  98
GLY B 103
1.74A
APR  B 201 (-3.5A)
APR  B 201 (-3.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PHE A 132
GLY A 130
PRO A  98
GLY A 103
1.71A
APR  A 201 (-3.7A)
APR  A 201 ( 3.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY C  47
VAL C 155
LEU C  53
GLY C 130
PHE C 132
1.56A
APR  C 201 (-4.3A)
APR  C 201 ( 4.9A)
None
APR  C 201 (-3.2A)
APR  C 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY E  47
VAL E 155
LEU E  53
GLY E 130
PHE E 132
1.56A
APR  E 201 (-4.4A)
APR  E 201 ( 4.9A)
None
APR  E 201 (-3.2A)
APR  E 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PHE C 132
GLY C 130
PRO C  98
GLY C 103
1.72A
APR  C 201 (-3.5A)
APR  C 201 (-3.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY E  46
VAL E 155
LEU E  53
GLY E 130
PHE E 132
1.47A
APR  E 201 (-3.9A)
APR  E 201 ( 4.9A)
None
APR  E 201 (-3.2A)
APR  E 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY A  47
VAL A 155
LEU A  53
GLY A 130
PHE A 132
1.53A
APR  A 201 (-4.1A)
APR  A 201 ( 4.8A)
None
APR  A 201 ( 3.2A)
APR  A 201 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY C  46
VAL C 155
LEU C  53
GLY C 130
PHE C 132
1.51A
APR  C 201 (-4.3A)
APR  C 201 ( 4.9A)
None
APR  C 201 (-3.2A)
APR  C 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY B  46
VAL B 155
LEU B  53
GLY B 130
PHE B 132
1.56A
EDO  B 202 (-3.9A)
None
None
APR  B 201 (-3.2A)
APR  B 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY C  47
VAL C 155
LEU C  53
GLY C 130
PHE C 132
1.39A
MES  C 201 ( 4.9A)
EDO  C 206 ( 4.2A)
None
MES  C 201 (-3.3A)
MES  C 201 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		6 / 12
GLY A  47
GLU B 170
VAL A 155
LEU A  53
GLY A 130
PHE A 132
1.40A
MES  A 201 ( 4.8A)
None
None
None
MES  A 201 (-3.1A)
MES  A 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		6 / 12
GLY A  46
GLU B 170
VAL A 155
LEU A  53
GLY A 130
PHE A 132
1.57A
MES  A 201 ( 4.9A)
None
None
None
MES  A 201 (-3.1A)
MES  A 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PHE A 132
GLY A 130
PRO A  98
GLY A 103
1.65A
MES  A 201 (-3.5A)
MES  A 201 (-3.1A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y6R_B_CTCB1385_0
(TETX2 PROTEIN)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PHE C 132
GLY C 130
PRO C  98
GLY C 103
1.67A
MES  C 201 (-3.6A)
MES  C 201 (-3.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
GLY B  47
VAL B 155
LEU B  53
GLY B 130
PHE B 132
1.41A
None
EDO  B 202 (-4.0A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		7btf NSP12
(SARS-CoV-2)		5 / 12
ARG A 555
GLN A 444
THR A 409
VAL A 410
GLN A 408
1.62A12.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		7btf NSP12
(SARS-CoV-2)		5 / 12
PHE A  45
HIS A 133
THR A 141
LEU A 247
ILE A 244
1.75A12.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		7btf NSP12
NSP7
(SARS-CoV-2)		5 / 12
PHE A 442
PRO A 412
VAL C  11
LEU C  55
ILE C  39
1.67A12.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		5 / 12
GLY A 120
LEU A  27
THR A  25
GLY A  23
VAL A  36
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		7bv1 NSP12
(SARS-CoV-2)		5 / 12
GLY A 345
PRO A 296
GLY A 352
PHE A 652
VAL A 299
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V2G_B_CTCB222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
HIS A 872
ASN A 874
HIS A 816
ARG A 836
PRO A 832
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FJ1_A_CTCA222_0
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		7bv1 NSP12
NSP8
(SARS-CoV-2)		5 / 12
HIS A 362
THR A 344
VAL A 342
LEU B 103
ILE B 107
1.79A12.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		7bv1 NSP12
(SARS-CoV-2)		5 / 12
GLY A 179
GLU A 180
VAL A 190
LEU A 316
ILE A 244
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TCT_A_CTCA222_0
(TETRACYCLINE
REPRESSOR)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
ARG A 555
GLN A 444
THR A 409
VAL A 410
GLN A 408
1.53A12.64
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5TUI_B_CTCB405_0
(TETRACYCLINE
DESTRUCTASE TET(50))		7bv2 NSP12
(SARS-CoV-2)		5 / 12
GLY A 179
GLU A 180
VAL A 190
LEU A 316
ILE A 244
1.53A
None